ATLAB Pharma and BZL Biologics Announce Exclusive Global Licensing Agreement for Lu-J591, a Novel Radiopharmaceutical in Phase IIB for the Treatment of Prostate Cancer
10/28/2011 9:50:02 AM
NANTES, France--(BUSINESS WIRE)--ATLAB Pharma SAS and BZL Biologics LLC have entered into a sublicense agreement to develop 177Lu-J591 for cancer treatment. It includes exclusive rights to manufacture, develop and commercialize this radiopharmaceutical product worldwide as well as a joint Phase IIB/III clinical validation program.
comments powered by